Who Paid My Doc
Dexycu
Drug Postoperative Inflammation
NDC 71879-001-01
General payments
$773,202
Research payments
$886,086
Through program year 2024, $773,202 in general payments and $886,086 in research payments were reported against Dexycu (Postoperative Inflammation).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
10 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $98,575 | 9 |
| 2023 | Research | $115,615 | 7 |
| 2022 | General | $108,774 | 605 |
| 2022 | Research | $117,040 | 7 |
| 2021 | General | $158,989 | 885 |
| 2021 | Research | $65,070 | 3 |
| 2020 | General | $194,369 | 592 |
| 2020 | Research | $380,322 | 27 |
| 2019 | General | $311,070 | 1,571 |
| 2019 | Research | $109,464 | 3 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2022.
The top 5 of 11 specialties; each share is of general payments naming this product to practitioners with a specialty in 2022. Each practitioner is counted under their primary specialty.
The top 5 of 36 states; each share is of general payments naming this product in 2022 where a state was reported.
Records
3,653 general · 56 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.